2009-01-12 13:02:01 -

Research and Markets (www.researchandmarkets.com/research/85629c/u_s_pharma_pricin) has announced the addition of Decision Resources, Inc.'s new report "U.S. Pharma Pricing Strategies: Case Studies and Future Considerations" to their offering.


How should a company price its drug when generic competition is about to impact a drug class" How significant a role does price play in distinguishing drugs in a crowded marketplace" In

this report, we examine three common small-molecule drug classes and six biologics to treat RA. These class and drug pricing examinations offer some unique strategic considerations regarding pricing in the face of generic erosion or a diverse market sector. We also review the changing business landscape and provide analogs that forecast the impact of generic erosion on pharma pricing strategies.


Get the Answers You Need to Shape Your Strategy


- In 2001, a generic version of the statin Mevacor entered the U.S. market. How did Mevacor's manufacturer, Merck, respond" How did makers of other branded Statins price their drugs in the face of initial"and subsequent"generics competition" How have sales and market share of Statins - both branded and generic - changed in the face of increasing generics competition"
- Most SSRIs are available generically in the United States, but the prices of branded SSRIs have increased year over year. Why do branded SSRI manufacturers continue to raise the prices of their drugs despite the market availability of lower-cost generic alternatives" Have branded SSRI manufacturers discovered pricing strategies to retain prescription and sales volume in the face of generics competition" If so, how successful are these strategies"
- Until Wyeth's Effexor went generic, all the branded SNRI prices steadily increased each year. How did Wyeth price its follow-on product, Effexor XR, in the wake of generic availability of Effexor" Was Wyeth's Effexor XR pricing strategy successful" How has Eli Lilly's SNRI Cymbalta fared in response to the availability of generic Effexor"
- The RA biologics space is a crowded and dynamic one with six drugs indicated for this indication in the United States. Does pricing play a role in competitive strategy in this market sector" If so, what pricing pitfalls must a company avoid when introducing a new biologic into this market"
Scope


- Case studies: Statins, selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine. Reuptake inhibitors (SNRIs) and biologics used to treat RA.
- Tables and figures: tracing the pricing history of featured drug classes and relative pricing within drug classes.
- Expert Commentary: Barrie G. James of Pharma Strategy Consulting discusses how the current economic and political landscape will affect pharma pricing possibilities.
Key Topics Covered:


- Strategic Considerations
- Stakeholder Implications
- Introduction
- Case Study #1: Statins
- Case Study #2: Antidepressants"SSRIs and SNRIs
- Case Study # 3: Rheumatoid Arthritis Biologics
- What Do These Case Studies Reveal About Pricing?
- Spectrum Expert Commentary: Outlook for Pharma Pricing in the Current Economic and Political Landscape
Companies Mentioned:


- Abbott
- Amgen
- AstraZeneca
- Bayer
- Biogen Idec
- Bristol-Myers Squibb
- Centocor
- Eli Lilly
- Forest Laboratories
- Genentech
- GlaxoSmithKline
- Merck & Co.
- Pfizer
- Schering-Plough
- Wyeth
For more information visit www.researchandmarkets.com/research/85629c/u_s_pharma_pricin





Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

Fax (USA): 646-607-1907

Fax (International): +353-1-481-1716